Drawing upon the earlier post by DS "The person I spoke to about...

Drawing upon the earlier post by DS
"The person I spoke to about this seemed to think that if there was tumor cell death as is implied then it is pretty massive (as a layman I think I am more frustrated that this significance is not clear in the announcements) and all that is needed to smash it out of the park is demonstrate the same without direct injection."

So far we know that direct injection appears to kill the tumor but of course as indicated by RH, its a low bar for success. So the big question arises as to the likelihood of delivering a iMyc peptide (Phylogica's proprietary Myc inhibitors) systemically - by mouth, by inhalation, by absorption through the skin, or by intravenous injection.

There is much to learn from the pioneering work by Laura Soucek and her team. Soucek knows this road well having firstly validated OmoMyc in transgenic mouse models. They have found that Omomyc 'natively' possesses cell penetrating activity and using intranasal administration, they have demonstrated that OmoMycCPP rapidly biodistributes to the lung and brain. So, Soucek has discovered a viable pharmacological strategy to translate her work into the clinic.

Outstanding for Soucek but equally outstanding for Phylogica.

iMycs target the same region on Myc that OmoMyc bind to and it is believed that the mechanism of action in all likelihoods is similar. Presumably Phylogica will not use an intranasal delivery system given the current focus is upon blood borne cancers where the standard method of treatment is IV infusion. Nonetheless, the success by Soucek highlights the potential for using traditional delivery systems to inhibit Myc in cancer.